Delving Into the Latest Integrated Continuous Glucose Monitoring Devices: An Interdisciplinary Approach With Case Discussions to Enhance Diabetes Care

This activity includes a patient perspective.

Program Description

Integrated continuous glucose monitoring (iCGM) devices have been shown to reduce the rate of clinical hypoglycemia across adults and adolescent populations with diabetes. An important role for pharmacists and pharmacy technicians is to assist in supporting individualized diabetes care plans and encouraging the review of data from a person’s iCGM device. Expert panelists will discuss health literacy and technology barriers affecting access to and uptake of iCGM devices. Strategies for pharmacists and pharmacy technicians to address these barriers through patient-focused education and share best practices in relation to the type of iCGM device a person with diabetes is wearing will be presented. Additionally, patient cases will be introduced to highlight a person-centered approach to diabetes care plans that address individual preferences and potential benefits of iCGM use. This program also features a patient perspective interview that will highlight a person with diabetes and their experience using an iCGM device.

Target audience: Retail pharmacists and pharmacy technicians

Type of activity: Application for pharmacists, knowledge for pharmacy technicians
Release date: May 24, 2023
Expiration date: July 24, 2023

Time to complete activity: 1.5 hours
Fee: Free

Learner Level: Advanced

Educational Objectives

At the completion of this activity, pharmacists will be able to:

• Identify the impact of integrated continuous glucose monitoring (iCGM) devices in assisting persons with diabetes in achieving recommended glycemic targets and improved clinical outcomes while reducing disease burden
• Explain how iCGM devices have evolved and improved the management of diabetes across different patient populations
• Examine the role of the pharmacist in supporting persons with diabetes during their journey with iCGM to improve sustainability and optimize diabetes management

At the completion of this activity, pharmacy technicians will be able to:

• Review the impact of integrated continuous glucose monitoring (iCGM) devices in assisting persons with diabetes in reducing disease burden
• Recognize how iCGM devices have evolved and improved the management of diabetes across different patient populations
• Articulate the role of the pharmacy technicians in supporting pharmacists and persons with diabetes during their journey with iCGM to improve diabetes management

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity numbers 0290-0000-23-074-L01-P and 0290-0000-23-075-L01-T. The activity is available for CE credit through July 24, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Diana Isaacs, PharmD, has the following financial relationships with commercial interests to disclose:
Consultant: Sanofi, Lifescan

Speakers Bureau: Dexcom, Abbott, Insulet, Medtronic, Novo Nordisk, Lilly

Christine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, has the following financial relationships with commercial interests to disclose:
Consultant: Novo Nordisk

Advisory Board Participant: Dexcom

Speakers Bureau: Abbott

Eugene E. Wright Jr, MD, has the following financial relationships with commercial interests to disclose:
Consultant: Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Embecta, GSK, Lilly, Medtronic, Sanofi.

Speakers Bureau: Abbott Diabetes Care, Bayer, Boehringer Ingelheim, GSK, Lilly, Sanofi

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Cara Liday, PharmD, CDCES

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms